Amgen Inc.'s Q3 2013 earnings call showed strong financial performance with increased sales, earnings, and raised guidance. Key strategic developments include international expansion and the successful acquisition of Onyx, which adds to Amgen's capabilities in oncology, specifically multiple myeloma. The upbeat tone from management, the robust sales figures, and promising pipeline updates likely signal a positive investor sentiment. The emphasis on strategic growth through international markets and innovative biologics could foster market confidence in the near term, resulting in a favorable short-term impact on the stock price.

[1]